Article
HLA-B*1502 allele is associated with a cross-reactivity pattern of cutaneous adverse reactions to antiepileptic drugs.
The Journal of international medical research - 1 Jan 2012
Wang J, Zhang J, Wu X, Yu P, Hong Z
Abstract excerpt
The US Food and Drug Administration has recommended genetic screening for the human leucocyte antigen-B (HLA-B)*1502 allele in patients of Asian ethnicity before starting carbamazepine therapy, to avoid the fatal adverse treatment-related events associated with this drug. The association between cross-reactivity to antiepileptic drugs (AEDs) and the HLA-B*1502 allele has been only rarely reported. Here, two...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
